First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
And the company says it won’t need to carry out another trial.
And that could affect the drug's third-line accelerated approval.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
A fresh licensing deal tidies up years of work between the two companies.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
